nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

01.04.2011

Heparin-induced thrombocytopenia: present and future

verfasst von: Adam Cuker

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic and potentially devastating complication of heparin therapy due to formation of platelet-activating antibodies against complexes of platelet factor 4 and heparin. Over the last several decades, great advances in our understanding of HIT have elevated a once enigmatic syndrome, the mere existence of which was doubted by the medical community, to a well-characterized disorder. Nevertheless, critical questions remain unanswered. The objective of this review is to examine our current understanding of the epidemiology, pathophysiology, diagnosis, and management of HIT and to highlight areas of future inquiry.

Visentin GP, Ford SE, Scott JP, Aster RH (1994) Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 93:81–88PubMed

Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C (1994) Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 71:247–251PubMed

Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P (1994) Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83:3232–3239PubMed

Warkentin TE (2004) History of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (eds) Heparin-induced thrombocytopenia, 3rd edn. Marcel Dekker, Basel, pp 1–23

Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710–2715PubMed

Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330–1335PubMed

Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A (2003) The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101:2955–2999PubMed

Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A (2006) Gender imbalance and risk factors interactions in heparin-induced thrombocytopenia. Blood 108:2937–2941PubMed

Warkentin TE, Maurer BT, Aster RH (2007) Heparin-induced thrombocytopenia associated with fondaparinux. N Eng J Med 356:2653–2655

10.

Rota E, Bazzan M, Fantino G (2008) Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 99:779–781PubMed

11.

Salem M, Elrefai S, Shrit MA, Warkentin TE (2010) Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. Thromb Haemost 104:1071–1072PubMed

12.

Ansell J, Slepchuk N Jr, Kumar R, Lopez A, Southard L, Deykin D (1980) Heparin induced thrombocytopenia: a prospective study. Thromb Haemost 43:61–65PubMed

13.

Green D, Martin GJ, Shoichet SH, DeBacker N, Bomalaski JS, Lind RN (1984) Thrombocytopenia in a prospective, randomized, double-blind trial of bovine and porcine heparin. Am J Med Sci 288:60–64PubMed

14.

Powers PJ, Kelton JC, Carter CJ (1984) Studies on the frequency of heparin-associated thrombocytopenia. Thromb Res 33:439–443PubMed

15.

Bailey RT, Ursick JA, Heim KL, Hilleman DE, Reich JW (1986) Heparin-associated thrombocytopenia: a prospective comparison of bovine lung heparin, manufactured by a new process, and porcine intestinal heparin. Drug Intell Clin Pharm 20:374–378PubMed

16.

Francis JL, Palmer GJ 3rd, Moroose R, Drexler A (2003) Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 75:17–22PubMed

17.

Smythe MA, Koerber JM, Mattson JC (2007) The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 131:1644–1649PubMed

18.

Gallus AS, Goodall KT, Beswick W, Chesterman CN (1980) Heparin-associated thrombocytopenia: case report and prospective study. Aust NZ J Med 10:25–31

19.

Malcolm ID, Wigmore TA, Steinbrecher UP (1979) Heparin-associated thrombocytopenia: low frequency in 104 patients treated with heparin of intestinal mucosal origin. Can Med Assoc J 120:1086–1088PubMed

20.

Lindhoff-Last E, Nakov R, Misselwitz F, Breddin HK, Bauersachs R (2002) Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular weight heparin. Br J Haematol 118:1137–1142PubMed

21.

Bauer TL, Arepally G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, Poncz M, McNulty S, Amiral J, Hauck WW, Edie RN, Mannion JD (1997) Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95:1242–1246PubMed

22.

Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG (2000) Impact of the patient population on the risk of heparin-induced thrombocytopenia. Blood 96:1703–1708PubMed

23.

Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y (1999) Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 99:2530–2536PubMed

24.

Warkentin TE, Roberts RS, Hirsh J, Kelton JG (2003) An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 163:2518–2524PubMed

25.

Lubenow N, Hinz P, Thomaschewski S, Lietz T, Vogler M, Ladwig A, Junger M, Nauck M, Schellong S, Wander K, Engel G, Ekkernkamp A, Greinacher A (2010) The severity of trauma determine the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 115:1797–1803PubMed

26.

Crowther MA, Cook DJ, Albert M, Williamson D, Meade M, Granton J, Skrobik Y, Langevin S, Mehta S, Hebert P, Guyatt GH, Geerts W, Rabbat C, Douketis J, Zytaruk N, Sheppard J, Greinacher A, Warkentin TE, Canadian Critical Care Trials Group (2010) The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 25:287–293

27.

Hutchison CA, Dasgupta I (2007) National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant 22:1680–1684PubMed

28.

Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, Turi S, Mac Gillavry MR, Hamulyak K, Theunissen IM, Hunt BJ, Buller HR (1999) Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 81:668–672PubMed

29.

Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, Priollet P, Cohen C, Yvelin N, Schved JF, Tournaire M, Borg JY (2001) Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 108:1134–1140PubMed

30.

Stein PD, Hull RD, Matta F, Yaekoub AY, Liang J (2009) Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med 122:919–930PubMed

31.

Burgess JK, Lindeman R, Chesterman CN, Chong BH (1995) Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol 91:761–766PubMed

32.

Gruel Y, Pouplard C, Lasne D, Magdelaine-Beuzelin C, Charroing C, Watier H (2004) The homozygous FcgammaRIIIa-158 V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood 104:2791–2793PubMed

33.

Harris K, Nguyen P, Van Cott EM (2008) Platelet PlA2 polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia. Am J Clin Pathol 129:282–286PubMed

34.

Carlsson LE, Lubenow N, Blumentritt C, Kempf R, Paperberg S, Schroder W, Eichler P, Herrmann FH, Santoso S, Greinacher A (2003) Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics 13:253–258PubMed

35.

Ziporen L, Li ZQ, Park KS, Sabnekar P, Liu WY, Arepally G, Shoenfeld Y, Kieber-Emmons T, Cines DB, Poncz M (1998) Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 92:3250–3259PubMed

36.

Li ZQ, Liu W, Park KS, Sachais BS, Arepally GM, Cines DB, Poncz M (2002) Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 99:1230–1236PubMed

37.

Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH (2001) Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia. J Lab Clin Med 138:22–31PubMed

38.

Newman PM, Chong BH (1999) Further characterization of antibody and antigen in heparin-induced thrombocytopenia. Br J Haematol 107:303–309PubMed

39.

Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS (2005) Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105:131–138PubMed

40.

Suh JS, Malik MI, Aster RH, Visentin GP (1997) Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 54:196–201PubMed

41.

Untch B, Ahmad S, Jeske WP, Messmore HL, Hoppensteadt DA, Walenga JM, Lietz H, Fareed J (2002) Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. Thromb Res 105:117–123PubMed

42.

Reilly MP, Taylor SM, Hartman NK, Arepally GM, Sachais BS, Cines DB, Poncz M, McKenzie SE (2001) Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIa. Blood 98:2442–2447PubMed

43.

Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, Kelton JG (1994) Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84:3691–3699PubMed

44.

Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkle JG, Saito T, Tybulewicz VL, Watson SP (1997) The Fc receptor gamm-chain and the tyrosine kinase Syk are essential for mouse platelets by collagen. EMBO J 16:2333–2341PubMed

45.

Blank M, Schoenfeld Y, Tavor S, Praprotnik S, Bofia MC, Weksler B, Walenga MJ, Amiral J, Eldor A (2002) Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 14:121–129PubMed

46.

Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y (2001) Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 97:3300–3302PubMed

47.

Arepally GM, Mayer IM (2001) Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 98:1252–1254PubMed

48.

Rauova L, Hirsch JD, Greene TK, Zhai L, Hayes VM, Kowalska MA, Cines DB, Poncz M (2010) Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood 116:5021–5031PubMed

49.

Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M (2006) Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 107:2346–2353PubMed

50.

Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG (2008) Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 6:1304–1312PubMed

51.

Cines DB, Rauova L, Arepally G, Reilly MP, McKenzie SE, Sachais BS, Poncz M. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher 22:31–36

52.

Arepally GM, Kamei S, Park KS, Kamei K, Li ZQ, Liu W, Siegel DL, Kisiel W, Cines DB, Poncz M (2000) Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood 95:1533–1540PubMed

53.

Warkentin TE (2005) New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 127:35S–45SPubMed

54.

Oliveira GB, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, Moliterno DJ, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Ohman EM, Granger CB, Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry Investigators (2008) Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Int Med 168:94–102

55.

Warkentin TE (1998) Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 35:9–16PubMed

56.

Warkentin TE (1993) Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121:535–555

57.

Warkentin TE, Kelton JG (2001) Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344:1286–1292PubMed

58.

Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A (2002) Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 122:37–42PubMed

59.

Rice L, Attisha WK, Drexler A, Francis JL (2002) Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 136:210–215PubMed

60.

Watkentin TE, Kelton JG (2001) Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135:502–506

61.

Nader ND, Khadra WZ, Reich NT, Bacon DR, Salerno TA, Panos AL (1999) Blood product use in cardiac revascularization: comparison of on- and off-pump techniques. Ann Thorac Surg 68:1640–1643PubMed

62.

Lillo Le-Louet A, Boutouyrie P, Alhenc-Gelas M, Le Beller C, Gautier I, Aiach M, Lasne D (2004) Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2:1882–1888PubMed

63.

Selleng S, Malowsky B, Strobe U, Wessel A, Itterman T, Wollert HG, Warkentin TE, Greinacher A (2010) Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost 8:30–36PubMed

64.

Cipolle RJ, Rodvold KA, Seifert R, Clarens R, Ramirez-Lassepas M (1983) Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients. Ther Drug Monit 5:205–211PubMed

65.

Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B, Eichler P, Volpel H, Potzsch B, Luz M (1999) Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia (HAT) investigators. Circulation 100:587–593PubMed

66.

Warkentin TE, Kelton JG (1996) A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:502–507PubMed

67.

Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S (1997) Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 56:12–16PubMed

68.

Hong AP, Cook DJ, Sigouin CS, Warkentin TE (2003) Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 101:3049–3051PubMed

69.

Meyer-Lindenberg A, Quenzel EM, Bierhoff E, Wolff H, Schindler E, Biniek R (1997) Fatal cerebral venous sinus thrombosis in heparin-induced thrombocytopenia. Eur Neurol 37:191–192PubMed

70.

Ernest D, Fisher MM (1991) Heparin-induced thrombocytopaenia complicated by bilateral adrenal haemorrhage. Intensive Care Med 17:238–240PubMed

71.

LaMonte MP, Brown PM, Hurstin MJ (2004) Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 32:976–980PubMed

72.

Benhamou AC, Gruel Y, Barsotti J, Castellani L, Marchand M, Guerois C, Leclerc MH, Delahousse B, Griguer P, Leroy J (1985) The white clot syndrome or heparin associated thrombocytopenia and thrombosis (WCS or HATT) (26 cases). Int Angiol 4:303–310PubMed

73.

Hall AV, Clark WF, Parbtani A (1992) Heparin-induced thrombocytopenia in renal failure. Clin Nephrol 38:86–89PubMed

74.

Lipton ME, Gould D (1992) Case report: heparin-induced thrombocytopenia—a complication presenting to the vascular radiologist. Clin Radiol 45:137–138PubMed

75.

Warkentin TE, Greinacher A (2009) Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf 8:129–144PubMed

76.

Warkentin TE, Hirte DW, Anderson DR, Wilson WE, O’Connell GJ, Lo RC (1994) Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med 97:489–491PubMed

77.

Warkentin TE (1996) Heparin-induced skin lesion. Br J Haematol 92:494–497PubMed

78.

Schinderwolf M, Kroll H, Ackermann H, Garbaraviciene J, Kaufmann R, Boehncke WH, Ludwig RJ, Lindhoff-Last E (2010) Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost 8:1486–1491

79.

Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006) Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759–765PubMed

80.

Cuker A, Arepally G, Crowther MA, Rice L, Datko F, Hook K, Propert KJ, Kuter DJ, Ortel TL, Konkle BA, Cines DB (2010) The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 8:2642–2650PubMed

81.

Messmore HL, Fabbrini N, Bird ML, Choudhury AM, Cerejo M, Prechel M, Jeske WP, Siddiqui A, Thethi I, Wehrmacher WH, Walenga JM (2010) Simple scoring system for the early management of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. doi:10.1076/029610387126

82.

Pouplard C, Gueret P, Fouassier M, Ternisien C, Trossaert M, Regina S, Gruel Y (2007) Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 5:1373–1379PubMed

83.

Bryant A, Low J, Austin S, Joseph JE (2008) Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T’s score and particle gel immunoassay. Br J Haematol 143:721–726PubMed

84.

Denys B, Stove V, Philippe J, Devreese K (2008) A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia. Thromb Res 123:137–145PubMed

85.

Amiral J (1999) Antigens involved in heparin-induced thrombocytopenia. Semin Hematol 36:7–11PubMed

86.

Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y (1999) Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 111:700–706PubMed

87.

Lo GK, Sigouin CS, Warkentin TE (2007) What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 82:1037–1043PubMed

88.

Martin-Toutain I, Settegrana C, Ankri A (2009) High levels of heparin-platelet factor 4 antibodies in patients with pseudothrombocytopenia: risk of misdiagnosis. J Thromb Haemost 7:1416–1418PubMed

89.

Pauzner R, Greinacher A, Selleng K, Althaus K, Shenkman B, Seligsohn U (2009) False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 7:1070–1074PubMed

90.

Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA (2005) Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2:2133–2137

91.

Bakchoul T, Giptner A, Najaoui A, Bein G, Santoso S, Sachs UJ (2009) Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 7:1260–1265PubMed

92.

Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A (2006) Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 76:420–426PubMed

93.

Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG (2005) Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 146:341–346PubMed

94.

Cuker A, Ortel TL (2009) ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT? Hematology Am Soc Hematol Educ Program 250–252

95.

Whitlatch NL, Kong DF, Metjian AD, Arepally GM, Ortel TL (2010) Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood 116:1761–1766PubMed

96.

Meyer O, Salama A, Pittet N, Schwind P (1999) Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet 354:1525–1526PubMed

97.

Sheridan D, Carter C, Kelton JG (1986) A diagnostic test for heparin-induced thrombocytopenia. Blood 67:27–30PubMed

98.

Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C (1991) A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 66:734–736PubMed

99.

Fratantoni JC, Pollet R, Gralnick HR (1975) Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods. Blood 45:395–401PubMed

100.

Lee DH, Warkentin TE, Denomme GA, Hayward CP, Kelton JG (1996) A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haematol 95:724–731PubMed

101.

Jy W, Mao WW, Horstman LL, Valant PA, Ahn YS (1999) A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb Haemost 82:1255–1259PubMed

102.

Tomer A (1997) A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 98:648–656PubMed

103.

Warkentin TE (2002) Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 126:1415–1423PubMed

104.

Price EA, Hayward CP, Moffat KA, Moore JC, Warkentin TE, Zehnder JL (2007) Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost 98:1357–1361PubMed

105.

Arepally GM, Ortel TL (2006) Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355:809–817PubMed

106.

Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF (1999) Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 106:629–635PubMed

107.

Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M (2000) Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96:846–851PubMed

108.

Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG, Argatroban-915 Investigators (2003) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163:1849–1856PubMed

109.

Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG, ARG-911 Study Investigators (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838–1843PubMed

110.

Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F (2006) Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 129:1407–1416PubMed

111.

Warkentin TE, Greinacher A, Koster A, Lincoff AM, American College of Chest Physicians (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:340S–380SPubMed

112.

Beiderlinden M, Treschan TA, Görlinger K, Peters J (2007) Argatroban anticoagulation in critically ill patients. Ann Pharmacother 41:749–754PubMed

113.

Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Pötzsch B (1999) Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 99:73–80PubMed

114.

Lubenow N, Eichler P, Lietz T, Greinacher A, Group HitInvestigators (2005) Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 3:2428–2436PubMed

115.

Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, François D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V, GEHT-HIT Study Group (2006) Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 108:1492–1496PubMed

116.

Cardenas GA, Deitcher SR (2005) Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia. Mayo Clin Proc 80:491–493PubMed

117.

Grubb KJ, Salehi P, Chedrawy EG (2010) Bivalirudin: alternative anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. Recent Pat Cardiovasc Drug Discov 5:20–24PubMed

118.

Kiser TH, Fish DN (2006) Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 26:452–460PubMed

119.

Boyce SW, Bandyk DF, Bartholomew JR, Frame JN, Rice L (2011) A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT study. Am J Ther 18:14–22

120.

Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow M, Arthur C, Rickard K, Gallo J, Lloyd J, Seshadri P, Chesterman CN, Australian HIT Study Group (2001) Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost 86:1170–1175PubMed

121.

Farner B, Eichler P, Kroll H, Greinacher A (2001) A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 85:947–949

122.

Magnani HN, Gallus A (2006) Heparin-induced thrombocytopenia (HIT). A report of 1, 478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 95:967–981PubMed

123.

Warkentin TE (2010) Agents for the treatment of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 24:755–775PubMed

124.

Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG (1997) The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Int Med 127:804–812PubMed

125.

Srinivasan AF, Rice L, Bartholomew JR, Rangaswamy C, La Perna L, Thompson JE, Murphy S, Baker KR (2004) Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Int Med 164:66–70

126.

Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK (2001) Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 85:435–440PubMed

127.

Harder S, Graff J, Klinkhardt U, von Hentig N, Walenga JM, Watanabe H, Osakabe M, Breddin HK (2004) Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time. Thromb Haemost 91:1137–1145PubMed

128.

Babcock RB, Dumper CW, Scharfman WB (1976) Heparin-induced immune thrombocytopenia. N Engl J Med 295:237–241PubMed

129.

Cimo PL, Moake JL, Weinger RS, Ben-Menachem YB, Khalil KG (1979) Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses. Am J Hematol 6:125–133PubMed

130.

Refaai MA, Chuang C, Menegus M, Blumberg N, Francis CW (2010) Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost 8:1419–1421PubMed

131.

Pötzsch B, Klövekorn WP, Madlener K (2000) Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 343:515PubMed

132.

Selleng S, Haneya A, Hirt S, Selleng K, Schmid C, Greinacher A (2008) Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood 112:4027

133.

Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B (1990) Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet 336:1077–1078PubMed

134.

Reilly MP, Sinha U, André P, Taylor SM, Pak Y, Deguzman FR, Nanda N, Pandey A, Stolla M, Bergmeier W, McKenzie SE (2010) PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood. doi:10.1182/blood-2010-03-274969

Titel: Heparin-induced thrombocytopenia: present and future
verfasst von: Adam Cuker
Publikationsdatum: 01.04.2011
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 3/2011
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-011-0569-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Anticoagulation in the management of venous thromboembolism in the cancer patient

Evidence-based approach to thrombophilia testing

Which patients with unprovoked VTE should receive extended anticoagulation? the minority

Antiplatelet agents in cardiovascular disease

Quality measures and benchmarking for warfarin therapy